Italia markets close in 5 hours 27 minutes

Terumo Corporation (TRUMF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
17,46+0,21 (+1,21%)
Alla chiusura: 02:44PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente17,25
Aperto18,16
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno17,26 - 18,16
Intervallo di 52 settimane12,48 - 19,84
Volume2.675
Media Volume1.808
Capitalizzazione26,439B
Beta (5 anni mensile)0,50
Rapporto PE (ttm)37,95
EPS (ttm)0,46
Prossima data utili07 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)0,17 (0,95%)
Data ex dividendo27 set 2024
Stima target 1AN/D
  • GlobeNewswire

    Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

    U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest

  • GlobeNewswire

    Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

    Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat